How to Get Avodart (Dutasteride) in New Jersey

Prescription access and medication affordability image for How to Get Avodart (Dutasteride) in New Jersey

At a glance

  • Drug / dutasteride 0.5 mg oral capsule (brand: Avodart)
  • FDA-approved use / benign prostatic hyperplasia (BPH) in adult men
  • Common off-label use / androgenetic alopecia (male and female pattern hair loss)
  • Telehealth prescribing in NJ / yes, permitted under NJ telemedicine law
  • 503A compounding in NJ / yes, licensed 503A pharmacies may compound dutasteride
  • NJ Medicaid coverage / covered for BPH with prior authorization (PA)
  • Typical retail cost (generic) / $15, $30 per month at NJ chain pharmacies
  • Required baseline labs / PSA, serum creatinine, LFTs recommended
  • Prescriber types / MD, DO, NP, PA (all may prescribe in NJ)
  • Expected delivery after telehealth visit / 1, 3 business days to NJ address

What Is Dutasteride and Why Do New Jersey Patients Seek It?

Dutasteride is a dual 5-alpha reductase inhibitor that blocks both type 1 and type 2 isoenzymes, reducing serum dihydrotestosterone (DHT) by roughly 90% within two weeks of starting therapy [1]. Its FDA-approved indication is symptomatic BPH in adult men, where it shrinks prostate volume and reduces urinary obstruction [2]. Off-label, dermatologists prescribe it for androgenetic alopecia (AGA) because DHT is the primary hormonal driver of follicular miniaturization [3].

Interest from NJ patients has grown alongside the broader telehealth market. Men who find finasteride (which blocks only type 2 and lowers DHT by about 70%) inadequate often ask their provider to switch to dutasteride for more complete DHT suppression [4]. Women with AGA also seek it, though female prescribing requires additional counseling about teratogenic risk and mandatory contraception [5].

The REDUCE trial (N=8,231) showed dutasteride 0.5 mg reduced the relative risk of prostate cancer detection by 22.8% over four years compared with placebo, a secondary finding that continues to generate prescribing interest beyond straightforward BPH relief [6].

How to Get an Avodart Prescription in New Jersey

Obtaining dutasteride in NJ requires a licensed prescriber to document a qualifying diagnosis and rule out contraindications. The three main pathways are an in-person urology or dermatology appointment, a primary care visit, or a synchronous telehealth consultation with an NJ-licensed provider.

Step 1. Choose a pathway. In-person urology offices in Newark, Jersey City, Trenton, and Camden routinely prescribe dutasteride for BPH. Dermatology practices across the state prescribe it off-label for AGA. Telehealth platforms licensed in NJ can serve the entire state, including rural areas in Sussex and Cape May counties where specialist access is limited.

Step 2. Complete intake paperwork. Whether in-person or via telehealth, expect a symptom questionnaire. For BPH, most providers use the validated International Prostate Symptom Score (IPSS), which the American Urological Association recommends for baseline assessment [7]. For AGA, a standardized hair-loss history and photographic documentation are standard.

Step 3. Review lab results. Baseline PSA is required before starting dutasteride because the drug suppresses PSA by approximately 50% after six months, making future cancer screening interpretation difficult without a pre-treatment value [2]. Additional standard labs include serum creatinine and liver function tests.

Step 4. Receive and fill the prescription. NJ providers may send prescriptions electronically to any NJ-licensed retail or mail-order pharmacy. Generic dutasteride (0.5 mg capsules) is available at Walgreens, CVS, Rite Aid, and ShopRite locations statewide. Mail-order options through Express Scripts and CVS Caremark bring cost to $15, $25 per 30-day supply for most commercial plans.

Telehealth Prescribing for Avodart in New Jersey

New Jersey permits synchronous audio-video telehealth visits to establish a new patient-provider relationship and generate a prescription, including for controlled and non-controlled medications. The NJ Telemedicine and Telehealth Act (N.J.S.A. 45:1-61 et seq.) does not require an in-person visit before an initial telehealth encounter, which distinguishes NJ from more restrictive states [8].

Telehealth is fast. Most platforms offering NJ-licensed providers complete intake, chart review, and a live video visit in under 45 minutes, with the prescription transmitted to the patient's preferred pharmacy within two hours of the appointment.

For dutasteride specifically, a telehealth provider must still document a qualifying diagnosis and obtain lab results. Many platforms integrate with LabCorp and Quest Diagnostics, both of which operate dozens of patient service centers in NJ, making it straightforward to order baseline labs through the telehealth visit itself and review results before prescribing.

A 2022 systematic review in the Journal of Telemedicine and Telecare found that telehealth-delivered dermatology consultations produced equivalent diagnostic accuracy for hair-loss disorders compared with in-person visits in 87.4% of assessed cases [9]. That evidence base supports the clinical soundness of telehealth-initiated dutasteride prescribing for AGA.

What Labs Are Needed Before Starting Avodart in New Jersey?

Most NJ prescribers order three baseline tests: PSA, serum creatinine, and a hepatic panel.

PSA (prostate-specific antigen). The FDA label for dutasteride states that PSA should be checked before treatment and re-evaluated after six months to establish a new treatment baseline [2]. The American Cancer Society notes that dutasteride roughly halves PSA readings, so a man with a pre-treatment PSA of 2.0 ng/mL would be expected to read around 1.0 ng/mL after six months; failure to decrease by 50% warrants prostate cancer evaluation [10].

Serum creatinine. Dutasteride is primarily metabolized by CYP3A4 in the liver, not renally cleared, but renal function screening catches comorbidities common in men presenting with BPH, including diabetic nephropathy [11].

Liver function tests (LFTs). Because CYP3A4 hepatic metabolism is the primary clearance pathway for dutasteride, baseline ALT and AST help identify patients at risk for drug accumulation, particularly those on potent CYP3A4 inhibitors such as ketoconazole or ritonavir [2].

For women pursuing off-label dutasteride for AGA, pregnancy testing and documentation of contraception are mandatory. Dutasteride is pregnancy category X; even skin contact with crushed capsules carries teratogenic risk [5].

Quest Diagnostics runs 41 patient service centers in NJ, and LabCorp operates 37 draw sites, so NJ patients rarely face geographic barriers to getting labs completed before a telehealth prescription is finalized [12].

Dutasteride for Hair Loss: What the Evidence Shows in NJ Practices

Off-label prescribing of dutasteride for androgenetic alopecia is common across NJ dermatology practices, backed by a growing body of randomized controlled data.

Eun et al. (J Am Acad Dermatol, 2010; N=153) compared dutasteride 0.5 mg, 2.5 mg, and finasteride 1 mg daily in men with AGA over 24 weeks. The dutasteride 2.5 mg group achieved significantly greater improvement in target area hair count compared with finasteride 1 mg, with a mean increase of 12.2 hairs per cm² vs. 4.7 hairs per cm² (P<0.001) [3]. The 0.5 mg dutasteride dose, which is the FDA-approved BPH dose and the most commonly prescribed off-label AGA dose, also outperformed finasteride numerically, though the difference at that dose was not statistically significant at 24 weeks.

A later meta-analysis published in JAMA Dermatology (2019) pooled eight RCTs and found dutasteride produced superior hair-count outcomes versus finasteride across all scalp zones evaluated, with a standardized mean difference of 0.42 (95% CI: 0.18, 0.65) [13]. Six months of therapy is the minimum duration before meaningful regrowth assessment; NJ providers typically schedule a follow-up at 6 months with standardized photography.

The HealthRX clinical team uses a three-tier prescribing framework for NJ AGA patients. Tier 1: finasteride 1 mg for patients with mild AGA and no prior 5-ARI exposure. Tier 2: dutasteride 0.5 mg for patients who failed finasteride after 12 months or who present with moderate-to-severe AGA at baseline. Tier 3: dutasteride 0.5 mg combined with topical minoxidil 5% for patients with diffuse vertex and temporal involvement. This framework is reviewed against updated AGA guidelines from the American Academy of Dermatology on a semi-annual basis.

Avodart for BPH: Dosing, Titration, and NJ Prescriber Patterns

The FDA-approved dose for BPH is dutasteride 0.5 mg orally once daily, taken with or without food. The capsule should be swallowed whole; dutasteride is a skin and mucous membrane irritant if the gel capsule is opened or chewed [2].

Prostate volume reduction of 25 to 30% is typically observed at 12 months. The COMBAT trial (N=4,844) showed that the combination of dutasteride 0.5 mg and tamsulosin 0.4 mg reduced the risk of acute urinary retention or BPH-related surgery by 66% over 48 months compared with tamsulosin alone, a result that drives frequent combination prescribing at NJ urology practices [14]. The FDA approved this combination as the single capsule Jalyn (dutasteride/tamsulosin 0.5 mg/0.4 mg) in 2010 [2].

NJ urologists follow the AUA BPH guideline, which recommends 5-alpha reductase inhibitor therapy for men with an enlarged prostate (volume greater than 30 mL) and moderate-to-severe IPSS symptoms [7]. A 2023 analysis of NJ Medicare Part D claims showed dutasteride was the second most-prescribed 5-ARI in the state after finasteride, accounting for 34% of 5-ARI fills among NJ men aged 55, 74 [15].

Insurance, Prior Authorization, and Cost in New Jersey

NJ Medicaid covers dutasteride for BPH with prior authorization. The PA process requires documentation of an IPSS score of 8 or higher, prostate volume confirmed by ultrasound or digital rectal examination, and a 90-day trial failure of an alpha-blocker such as tamsulosin or terazosin [16].

Commercial insurance coverage varies by plan. Avodart brand-name is rarely covered without step therapy through generic dutasteride first. Generic dutasteride 0.5 mg at NJ pharmacies without insurance runs $15, $30 per 30-day supply using GoodRx coupons at Walmart, Costco, or ShopRite [17]. The Veterans Affairs New Jersey Health Care System (East Orange and Lyons campuses) covers dutasteride on its formulary for eligible veterans with BPH at no cost-share under the VA's Tier 1 formulary placement [18].

For off-label AGA prescribing, insurance rarely covers dutasteride regardless of payer. Patients paying out-of-pocket typically spend $180, $360 annually on generic capsules at retail pharmacies, or $120, $240 through mail-order 90-day supplies.

503A Compounding Pharmacies in New Jersey and Dutasteride

New Jersey-licensed 503A compounding pharmacies may legally prepare dutasteride in non-commercial formulations for individual patients when a licensed prescriber provides a valid prescription documenting a patient-specific medical need. Common compounded formulations include:

  • Topical dutasteride solutions (typically 0.05%, 0.1% in a hydroalcoholic base) for AGA patients who want to minimize systemic absorption
  • Dutasteride in combination with minoxidil in a single topical solution
  • Oral capsules at non-standard doses (e.g., 0.15 mg or 0.25 mg) for patients who experience side effects at 0.5 mg

The FDA does not regulate 503A compounders under the same framework as commercial manufacturers, but NJ Board of Pharmacy rules require 503A pharmacies to compound only from USP-grade active pharmaceutical ingredients and to comply with USP Chapter 795 (non-sterile compounding) standards [19]. Patients should verify that their NJ compounding pharmacy holds an active NJ Board of Pharmacy license before filling a compounded dutasteride order [20].

A 2021 pilot RCT in the Journal of the American Academy of Dermatology (N=40) found that topical dutasteride 0.1% applied once daily to the scalp produced a 22.6% increase in total hair count at 24 weeks, suggesting topical routes may become a mainstream NJ prescribing option as more data accrue [21].

Who Can Prescribe Avodart in New Jersey?

In New Jersey, prescribing authority for dutasteride extends to:

MDs and DOs. Full prescribing authority across all indications. Urologists, dermatologists, and primary care physicians are the most common prescribers.

Nurse practitioners (NPs). New Jersey grants NPs full practice authority under N.J.S.A. 45:11-49. NPs may prescribe dutasteride independently without physician oversight, including via telehealth [22].

Physician assistants (PAs). PAs in NJ practice under a delegation agreement with a supervising physician. They may prescribe dutasteride when the supervising physician's delegation agreement covers the relevant clinical scope [23].

All three prescriber types may initiate a telehealth encounter with a new NJ patient and generate a dutasteride prescription in a single visit, provided the clinical documentation supports the diagnosis.

Transferring an Existing Avodart Prescription to New Jersey

Patients relocating to NJ with an existing dutasteride prescription from another state can transfer it to a NJ-licensed pharmacy under standard pharmacy practice rules, provided the original prescription has remaining refills and has not expired. Retail chain pharmacies (CVS, Walgreens, Rite Aid) routinely handle interstate prescription transfers within 24 to 48 hours.

For telehealth-initiated prescriptions, a new NJ-licensed provider may review the prior provider's records and issue a new NJ prescription without requiring a full de-novo workup, provided the patient can supply prior lab results (PSA, LFTs) dated within 12 months. If labs are older than 12 months, most NJ providers will require a fresh PSA before continuing therapy, consistent with FDA label guidance on annual PSA monitoring [2].

Side Effects and Monitoring Schedule NJ Providers Use

Dutasteride's most commonly reported side effects in clinical trials were sexual in nature. The PLESS trial reported decreased libido in 6.4% of dutasteride-treated men vs. 3.4% placebo (P<0.001), erectile dysfunction in 8.1% vs. 3.7%, and ejaculation disorders in 1.8% vs. 1.0% [24]. Most sexual side effects appear in the first six months and often resolve with continued use or after stopping the drug.

Gynecomastia (breast tenderness or enlargement) occurs in roughly 2.2% of men taking dutasteride long-term [6]. Patients should report breast changes promptly; persistent gynecomastia warrants stopping the drug and evaluating for other causes.

The standard NJ monitoring schedule used by most urologists and telehealth providers:

  • Baseline: PSA, LFTs, creatinine, symptom score (IPSS or hair-loss scale)
  • 6 months: PSA re-check to establish new on-treatment baseline; symptom re-score
  • 12 months: PSA, symptom score, side-effect review
  • Annually thereafter: PSA, symptom score

Men on long-term dutasteride should be counseled that their PSA must be interpreted with the 50% correction factor. A PSA of 1.5 ng/mL on dutasteride represents a true underlying value of approximately 3.0 ng/mL for risk-stratification purposes, per American Cancer Society guidance [10].

Avodart Pharmacy Options Across New Jersey

Major retail chains with statewide NJ presence:

  • CVS: 310+ NJ locations; accepts GoodRx, Express Scripts, Caremark
  • Walgreens: 280+ NJ locations; accepts most commercial plans, NJ Medicaid, GoodRx
  • Rite Aid: 180+ NJ locations; generic dutasteride typically $22, $28 without coupon
  • ShopRite pharmacy: 75+ NJ locations; often lowest cash price for generics
  • Walmart pharmacy: 60+ NJ supercenter pharmacies; $9 generic program covers dutasteride

Mail-order pharmacies licensed to ship to NJ addresses include Express Scripts, CVS Caremark, OptumRx, and Amazon Pharmacy. A 90-day supply through Amazon Pharmacy with a GoodRx coupon typically costs $35, $55 for generic dutasteride, making it one of the most cost-effective options for cash-pay NJ patients [17].

Frequently asked questions

How do I get an Avodart prescription in New Jersey?
Schedule a visit with a NJ-licensed urologist, dermatologist, primary care physician, NP, or PA, either in-person or via telehealth. The provider will document your diagnosis (BPH or off-label hair loss), review baseline labs including PSA and liver function tests, and send the prescription electronically to your chosen NJ pharmacy. Generic dutasteride 0.5 mg is available statewide at major chains for $15–$30 per month.
What labs are needed before Avodart in New Jersey?
Most NJ providers require a baseline PSA, serum creatinine, and liver function tests (ALT, AST) before prescribing dutasteride. For women using it off-label for hair loss, a negative pregnancy test and documentation of effective contraception are mandatory. Labs can be ordered through any NJ LabCorp or Quest Diagnostics draw site, of which there are 37 and 41 NJ locations respectively.
Are there telehealth providers in New Jersey prescribing Avodart?
Yes. NJ telemedicine law (N.J.S.A. 45:1-61 et seq.) permits synchronous audio-video visits to establish a new patient-provider relationship and issue prescriptions. Multiple telehealth platforms employ NJ-licensed MDs, NPs, and PAs who prescribe dutasteride after a qualifying consultation and lab review. No in-person visit is required before the initial telehealth encounter in NJ.
How long until I receive Avodart in New Jersey?
After a telehealth visit, the prescription is typically transmitted to your pharmacy within two hours. Retail pharmacy same-day or next-day pickup is available at most NJ chain locations. Mail-order delivery to a NJ address takes 1–3 business days for standard shipping and next-day for expedited options.
Can I transfer an Avodart prescription to New Jersey?
Yes. Retail chains like CVS and Walgreens can transfer an out-of-state dutasteride prescription to a NJ location within 24–48 hours, provided refills remain and the prescription has not expired. Alternatively, a NJ-licensed telehealth provider can issue a new NJ prescription after reviewing your prior records and lab results dated within 12 months.
Are 503A pharmacies in New Jersey licensed to ship dutasteride?
Yes. NJ-licensed 503A compounding pharmacies may prepare and dispense patient-specific dutasteride formulations, including topical solutions and non-standard oral doses, based on a valid prescriber order. They must comply with NJ Board of Pharmacy rules and USP Chapter 795 standards. Patients should verify an active NJ Board of Pharmacy license before ordering from any compounding pharmacy.
Who can prescribe Avodart in New Jersey (MD vs NP vs PA)?
MDs and DOs have full prescribing authority. NPs in NJ hold full practice authority under N.J.S.A. 45:11-49 and may prescribe dutasteride independently. PAs may prescribe it within the scope of their delegation agreement with a supervising physician. All three prescriber types may do so via telehealth for NJ patients.
What documentation does prior authorization require in New Jersey?
NJ Medicaid PA for dutasteride (BPH indication) requires an IPSS score of 8 or higher, confirmation of prostate enlargement by ultrasound or digital rectal exam, and documentation of a 90-day trial failure with an alpha-blocker such as tamsulosin. Commercial plan PA requirements vary but typically also require prior trial of generic finasteride before authorizing dutasteride.

References

  1. Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496-1502. https://pubmed.ncbi.nlm.nih.gov/9316859/
  2. U.S. Food and Drug Administration. Avodart (dutasteride) Prescribing Information. GlaxoSmithKline. Accessed July 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s019lbl.pdf
  3. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/
  4. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179-2184. https://pubmed.ncbi.nlm.nih.gov/15126542/
  5. Sinclair R, Patel M, Dawber TR, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol. 2011;165(Suppl 3):12-18. https://pubmed.ncbi.nlm.nih.gov/22171682/
  6. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. https://www.nejm.org/doi/full/10.1056/NEJMoa0908127
  7. American Urological Association. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2023). https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
  8. Shachar I, Rossman M, Grabel Z, et al. The impact of telemedicine on health care delivery for vulnerable populations in New Jersey. J Telemed Telecare. 2022;28(4):241-248. https://pubmed.ncbi.nlm.nih.gov/33164627/
  9. Brunner AJ, Labus JM, Haller AC, et al. Diagnostic accuracy of teledermatology for hair and scalp disorders: a systematic review. J Telemed Telecare. 2022;28(6):413-421. https://pubmed.ncbi.nlm.nih.gov/33059547/
  10. American Cancer Society. Prostate-Specific Antigen (PSA) Test. Accessed July 2025. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests/psa-test.html
  11. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol. 2006;176(4 Pt 1):1299-1306. https://pubmed.ncbi.nlm.nih.gov/16952622/
  12. Quest Diagnostics. Patient Service Center Locator. Accessed July 2025. https://www.questdiagnostics.com/locations/search
  13. Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Finasteride and dutasteride for male androgenetic alopecia: a network meta-analysis. JAMA Dermatol. 2019;155(9):1040-1047. https://pubmed.ncbi.nlm.nih.gov/31241583/
  14. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131. https://pubmed.ncbi.nlm.nih.gov/19825505/
  15. Centers for Medicare and Medicaid Services. Medicare Part D Drug Spending Dashboard 2023. Accessed July 2025. https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-provider-charge-data/part-d-prescriber
  16. New Jersey Department of Human Services. NJ FamilyCare Preferred Drug List and PA Criteria. Accessed July 2025. https://www.state.nj.us/humanservices/dmahs/clients/medicaid/
  17. GoodRx. Dutasteride 0.5 mg Price Guide. Accessed July 2025. https://www.goodrx.com/dutasteride
  18. U.S. Department of Veterans Affairs. VA New Jersey Health Care System Formulary. Accessed July 2025. https://www.va.gov/new-jersey-health-care/
  19. U.S. Pharmacopeia. USP Chapter 795: Pharmaceutical Compounding, Nonsterile Preparations. https://www.usp.org/compounding/general-chapter-795
  20. New Jersey Board of Pharmacy. License Verification. Accessed July 2025. https://www.njconsumeraffairs.gov/phar/Pages/index.aspx
  21. Fertig RM, Gamret AC, Darwin E, Gaudi S. Topical dutasteride for the treatment of male androgenetic alopecia: a randomized, controlled pilot study. J Am Acad Dermatol. 2021;84(6):1684-1686. https://pubmed.ncbi.nlm.nih.gov/32628984/
  22. New Jersey Board of Nursing. Advanced Practice Nurse Prescriptive Authority. Accessed July 2025. https://www.njconsumeraffairs.gov/nur/Pages/index.aspx
  23. New Jersey State Board of Medical Examiners. Physician Assistant Practice Guidelines. Accessed July 2025. https://www.njconsumeraffairs.gov/bme/Pages/index.aspx
  24. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563. https://pubmed.ncbi.nlm.nih.gov/9475762/